Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454777 | 0.73 | POLB (0.49) | KIF11DNMT1 | |
| SCHEMBL4158244 | 0.73 | KDM4E (0.50) | KIF11CPA1DNMT1 | |
| SCHEMBL4839273 | 0.72 | CYP1A2 (0.48) | KIF11CPA1 | |
| SCHEMBL4831433 | 0.72 | CYP1A2 (0.48) | KIF11CPA1 | |
| SCHEMBL4839082 | 0.71 | KIF11 (0.43) | KIF11DNMT1 | |
| SCHEMBL4838957 | 0.70 | KIF11 (0.44) | KIF11MMEACEDNMT1 | |
| SCHEMBL5870483 | 0.69 | CTSS (0.37) | METAP2METAP1MMEACECPA1 | |
| SCHEMBL5870481 | 0.69 | CTSS (0.37) | METAP2METAP1MMEACECPA1 | |
| SCHEMBL134594 | 0.69 | HSD17B10 (0.51) | KIF11 | |
| SCHEMBL4831186 | 0.68 | SRR (0.51) | KIF11MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365091-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2008-04-29 | — | — | US | disclosed |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2006-12-21 | — | — | US | disclosed |
| US-7105539-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | disclosed |
| EP-1572645-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | Enobia Pharma Inc. (CA) | 2005-09-14 | — | — | EP | disclosed |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | BIOMEP INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004050620-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | ENOBIA PHARMA (CA) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | GLS, SUCNR1, PGD | KIF11 4827/4885METAP2 1414/4885METAP1 611/4885 |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, PGD | KIF11 4807/4885METAP2 1517/4885METAP1 589/4885 |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, GCDH | KIF11 4782/4885METAP2 1637/4885METAP1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.